Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures.

Parasramka MA, Ali S, Banerjee S, Deryavoush T, Sarkar FH, Gupta S.

Mol Nutr Food Res. 2013 Feb;57(2):235-48. doi: 10.1002/mnfr.201200297. Epub 2013 Jan 7.

PMID:
23293055
2.

Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells.

Parasramka MA, Gupta SV.

Nutr Cancer. 2011;63(3):456-65. doi: 10.1080/01635581.2011.535962.

PMID:
21462088
3.

MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.

Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T, Takahata S, Toma H, Nagai E, Tanaka M.

Mol Cancer Ther. 2009 May;8(5):1067-74. doi: 10.1158/1535-7163.MCT-08-0592. Epub 2009 May 12.

4.

Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.

Brandi G, Tavolari S, Guarnieri T, Di Marco M, Paterini P, Macchini M, Di Girolamo S, Papi A, De Rosa F, Biasco G.

Pancreas. 2014 Jan;43(1):53-63. doi: 10.1097/MPA.0b013e3182a6486e.

PMID:
24201777
6.

Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.

Chaudhary AK, Mondal G, Kumar V, Kattel K, Mahato RI.

Cancer Lett. 2017 Aug 28;402:1-8. doi: 10.1016/j.canlet.2017.05.007. Epub 2017 May 20.

PMID:
28536008
7.

Combined effect of microRNA, nutraceuticals and drug on pancreatic cancer cell lines.

Pandita A, Manvati S, Singh SK, Vaishnavi S, Bamezai RN.

Chem Biol Interact. 2015 May 25;233:56-64. doi: 10.1016/j.cbi.2015.03.018. Epub 2015 Apr 1.

PMID:
25841339
8.

{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.

Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, Koca C, Yadav VR, Tong Z, Gelovani JG, Guha S, Krishnan S, Aggarwal BB.

Cancer Res. 2010 Nov 1;70(21):8695-705. doi: 10.1158/0008-5472.CAN-10-2318. Epub 2010 Sep 23.

9.

Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells.

Chen J, Wu SY, Ou-Yang ZG, Zhen YS.

Acta Pharmacol Sin. 2008 May;29(5):614-9. doi: 10.1111/j.1745-7254.2008.00774.x.

10.

MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.

Rajabpour A, Afgar A, Mahmoodzadeh H, Radfar JE, Rajaei F, Teimoori-Toolabi L.

Cancer Chemother Pharmacol. 2017 Oct;80(4):765-775. doi: 10.1007/s00280-017-3418-2. Epub 2017 Sep 8.

PMID:
28887583
11.

Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.

Hering J, Garrean S, Dekoj TR, Razzak A, Saied A, Trevino J, Babcock TA, Espat NJ.

Ann Surg Oncol. 2007 Dec;14(12):3620-8. Epub 2007 Sep 26.

PMID:
17896154
12.

[Role of nuclear factor-kappaB on emodin-induced sensitization of pancreatic cancer to gemcitabine].

Liu A, Hu YS, Wang ZH, Tang LL, Ke PY, Lin SZ.

Yao Xue Xue Bao. 2011 Feb;46(2):146-52. Chinese.

PMID:
21542284
13.

Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-κB.

Liu A, Chen H, Tong H, Ye S, Qiu M, Wang Z, Tan W, Liu J, Lin S.

Mol Med Rep. 2011 Mar-Apr;4(2):221-7. doi: 10.3892/mmr.2011.414. Epub 2011 Jan 3.

PMID:
21468555
14.

Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.

Bu HQ, Luo J, Chen H, Zhang JH, Li HH, Guo HC, Wang ZH, Lin SZ.

Int J Oncol. 2012 Sep;41(3):949-58. doi: 10.3892/ijo.2012.1519. Epub 2012 Jun 14.

PMID:
22710877
15.

Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.

Dong J, Zhao YP, Zhou L, Zhang TP, Chen G.

Arch Med Res. 2011 Jan;42(1):8-14. doi: 10.1016/j.arcmed.2011.01.006.

PMID:
21376256
16.

Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.

Fryer RA, Barlett B, Galustian C, Dalgleish AG.

Anticancer Res. 2011 Nov;31(11):3747-56.

PMID:
22110196
17.

Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.

Holcomb BK, Yip-Schneider MT, Waters JA, Beane JD, Crooks PA, Schmidt CM.

J Gastrointest Surg. 2012 Jul;16(7):1333-40. doi: 10.1007/s11605-012-1913-7. Epub 2012 May 23.

PMID:
22618517
18.

Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.

Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, Sarkar FH.

Cancer Res. 2010 May 1;70(9):3606-17. doi: 10.1158/0008-5472.CAN-09-4598. Epub 2010 Apr 13.

19.

Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol.

Paik WH, Kim HR, Park JK, Song BJ, Lee SH, Hwang JH.

Anticancer Res. 2013 Apr;33(4):1473-81.

PMID:
23564788
20.

Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.

Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I, Fasciani A, Boschi E, Campani D, Bevilacqua G, Mosca F, Del Tacca M.

Eur J Pharmacol. 2004 Sep 13;498(1-3):9-18.

PMID:
15363970

Supplemental Content

Support Center